Screener
Kailera Therapeutics KLRA Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Kailera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Kailera Therapeutics’s 10-Q, filed May 26, 2026.
- Filed
- May 26, 2026, 4:29 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-239417
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net loss | $(78,865) | $(17,983) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization expense | 101 | 63 |
| Stock-based compensation expense | 3,939 | 1,523 |
| Change in fair value of preferred stock tranche right liability | - | (800) |
| Non-cash lease expense | 293 | (13) |
| Accretion of discounts on investments, net | (1,225) | - |
| Other | (19) | (7) |
Item 1. Financial Statements.
FAQ
- What is Kailera Therapeutics's stock-based comp?
- Kailera Therapeutics (KLRA) reported stock-based comp of $3.94M in Q1 2026.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Kailera Therapeutics's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude